secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001077183-26-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M
---------------------------------------------------------------------------

- Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.
- Net loss narrowed 34% to $17M; adjusted EBITDA $9M (+27% YoY).
- Raised FY2026 revenue guidance to $797-803M (prior range not specified).
- Launched RaDaR ST MRD assay; received MolDX coverage for PanTracer LBx.
- Cash and marketable securities $146M at quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/0001077183-26-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/neo-20260428.htm
  HTML page:      https://secwatch.observer/filing/0001077183-26-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer